ArticleFrontiers in oncology2026
Case Report: Diffuse peribiliary metastasis from ovarian cancer mimicking sclerosing cholangitis without a detectable mass.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer typically spreads via peritoneal seeding, hematogenous, or lymphatic routes. Bile duct metastasis is extremely rare, and peribiliary metastasis manifesting as diffuse Glissonian sheath infiltration without a detectable mass lesion, to our knowledge, has not been well documented. Case presentation: A 42-year-old woman with stage IVB high-grade serous ovarian carcinoma, previously treated with cytoreductive surgery and multiple lines of chemotherapy, presented with fatigue, anorexia, and mild jaundice. Magnetic resonance cholangiopancreatography (MRCP) revealed bile duct wall thickening, peribiliary edema (Glissonian sheath edema), and diffuse inflammatory changes without a discrete mass. Autoimmune and infectious workups were negative. Endoscopic retrograde cholangiopancreatography (ERCP) with biopsy showed micropapillary clusters of atypical cells. Immunohistochemistry was positive for CK7, CK19, PAX-8, P16, and mutant-type p53; CEA focally positive; ER negative; Ki-67 high. This confirmed metastatic high-grade serous carcinoma of ovarian origin involving the common bile duct wall. Imaging (MRI/MRCP) suggested diffuse peribiliary involvement compatible with Glissonian sheath infiltration, although the small biopsy did not directly sample the intrahepatic sheath itself. We hypothesize that the radiological changes reflect peribiliary lymphatic spread, but this remains an inference based on imaging-pathology correlation rather than a histologically proven mechanism. Effective biliary drainage could not be achieved because the patient was unable to tolerate the nasobiliary drain. She was discharged against medical advice and died shortly thereafter, according to family report. Conclusions: In cancer patients with unexplained cholestasis, peribiliary metastasis should be considered even when no mass is seen on cross-sectional imaging. ERCP with biopsy and immunohistochemistry are essential for diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.